vs
Alight, Inc.（ALIT）与莫德纳（MRNA）财务数据对比。点击上方公司名可切换其他公司
莫德纳的季度营收约是Alight, Inc.的1.6倍（$1.0B vs $653.0M），莫德纳净利率更高（-19.7% vs -142.7%，领先123.0%），Alight, Inc.同比增速更快（-4.0% vs -45.4%），Alight, Inc.自由现金流更多（$99.0M vs $-880.0M），过去两年Alight, Inc.的营收复合增速更高（8.1% vs -45.0%）
Alight公司是一家美国信息技术与咨询企业，专注于人力资源相关业务，主打基于云的系统服务、业务外包与咨询服务，为大型企业提供人力资本管理平台与外包方案，业务范围涵盖健康福利管理、财务管理以及退休规划等领域。
莫德纳是一家总部位于美国马萨诸塞州剑桥市的生物制药企业，深耕RNA治疗领域，核心业务聚焦mRNA疫苗研发。其疫苗通过信使RNA（mRNA）分子拷贝传递蛋白合成指令以触发人体免疫反应，公司名称由“修饰”“RNA”与“现代”三个词组合而来。
ALIT vs MRNA — 直观对比
营收规模更大
MRNA
是对方的1.6倍
$653.0M
营收增速更快
ALIT
高出41.5%
-45.4%
净利率更高
MRNA
高出123.0%
-142.7%
自由现金流更多
ALIT
多$979.0M
$-880.0M
两年增速更快
ALIT
近两年复合增速
-45.0%
损益表 — Q4 FY2025 vs Q3 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $653.0M | $1.0B |
| 净利润 | $-932.0M | $-200.0M |
| 毛利率 | 36.8% | 79.6% |
| 营业利润率 | -114.9% | -25.6% |
| 净利率 | -142.7% | -19.7% |
| 营收同比 | -4.0% | -45.4% |
| 净利润同比 | -11750.0% | -1638.5% |
| 每股收益（稀释后） | $-1.77 | $-0.51 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ALITMRNA
| Q4 25 | $653.0M | — | ||
| Q3 25 | $533.0M | $1.0B | ||
| Q2 25 | $528.0M | — | ||
| Q1 25 | $548.0M | — | ||
| Q4 24 | $680.0M | $966.0M | ||
| Q3 24 | $555.0M | $1.9B | ||
| Q2 24 | $538.0M | — | ||
| Q1 24 | $559.0M | — |
净利润ALITMRNA
| Q4 25 | $-932.0M | — | ||
| Q3 25 | $-1.1B | $-200.0M | ||
| Q2 25 | $-1.1B | — | ||
| Q1 25 | $-25.0M | — | ||
| Q4 24 | $8.0M | $-1.1B | ||
| Q3 24 | $-74.0M | $13.0M | ||
| Q2 24 | $23.0M | — | ||
| Q1 24 | $-114.0M | — |
毛利率ALITMRNA
| Q4 25 | 36.8% | — | ||
| Q3 25 | 33.4% | 79.6% | ||
| Q2 25 | 33.3% | — | ||
| Q1 25 | 31.2% | — | ||
| Q4 24 | 39.9% | 23.5% | ||
| Q3 24 | 31.4% | 72.4% | ||
| Q2 24 | 31.0% | — | ||
| Q1 24 | 32.6% | — |
营业利润率ALITMRNA
| Q4 25 | -114.9% | — | ||
| Q3 25 | -248.0% | -25.6% | ||
| Q2 25 | -191.3% | — | ||
| Q1 25 | -1.5% | — | ||
| Q4 24 | 6.5% | -129.0% | ||
| Q3 24 | -7.6% | -3.8% | ||
| Q2 24 | -9.7% | — | ||
| Q1 24 | -7.2% | — |
净利率ALITMRNA
| Q4 25 | -142.7% | — | ||
| Q3 25 | -200.2% | -19.7% | ||
| Q2 25 | -203.2% | — | ||
| Q1 25 | -4.6% | — | ||
| Q4 24 | 1.2% | -115.9% | ||
| Q3 24 | -13.3% | 0.7% | ||
| Q2 24 | 4.3% | — | ||
| Q1 24 | -20.4% | — |
每股收益（稀释后）ALITMRNA
| Q4 25 | $-1.77 | — | ||
| Q3 25 | $-2.02 | $-0.51 | ||
| Q2 25 | $-2.03 | — | ||
| Q1 25 | $-0.05 | — | ||
| Q4 24 | $0.02 | $-2.91 | ||
| Q3 24 | $-0.14 | $0.03 | ||
| Q2 24 | $0.04 | — | ||
| Q1 24 | $-0.21 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $273.0M | $1.1B |
| 总债务越低越好 | $2.0B | — |
| 股东权益账面价值 | $1.0B | $9.3B |
| 总资产 | $4.6B | $12.1B |
| 负债/权益比越低杠杆越低 | 1.92× | — |
8季度趋势，按日历期对齐
现金及短期投资ALITMRNA
| Q4 25 | $273.0M | — | ||
| Q3 25 | $205.0M | $1.1B | ||
| Q2 25 | $227.0M | — | ||
| Q1 25 | $223.0M | — | ||
| Q4 24 | $343.0M | $1.9B | ||
| Q3 24 | $300.0M | $1.6B | ||
| Q2 24 | $183.0M | — | ||
| Q1 24 | $256.0M | — |
总债务ALITMRNA
| Q4 25 | $2.0B | — | ||
| Q3 25 | $2.0B | — | ||
| Q2 25 | $2.0B | — | ||
| Q1 25 | $2.0B | — | ||
| Q4 24 | $2.0B | — | ||
| Q3 24 | $2.0B | — | ||
| Q2 24 | $2.8B | — | ||
| Q1 24 | $2.8B | — |
股东权益ALITMRNA
| Q4 25 | $1.0B | — | ||
| Q3 25 | $2.0B | $9.3B | ||
| Q2 25 | $3.1B | — | ||
| Q1 25 | $4.2B | — | ||
| Q4 24 | $4.3B | $10.9B | ||
| Q3 24 | $4.3B | $11.9B | ||
| Q2 24 | $4.5B | — | ||
| Q1 24 | $4.5B | — |
总资产ALITMRNA
| Q4 25 | $4.6B | — | ||
| Q3 25 | $5.5B | $12.1B | ||
| Q2 25 | $6.8B | — | ||
| Q1 25 | $7.9B | — | ||
| Q4 24 | $8.2B | $14.1B | ||
| Q3 24 | $8.3B | $15.8B | ||
| Q2 24 | $10.5B | — | ||
| Q1 24 | $10.7B | — |
负债/权益比ALITMRNA
| Q4 25 | 1.92× | — | ||
| Q3 25 | 1.00× | — | ||
| Q2 25 | 0.65× | — | ||
| Q1 25 | 0.48× | — | ||
| Q4 24 | 0.47× | — | ||
| Q3 24 | 0.47× | — | ||
| Q2 24 | 0.62× | — | ||
| Q1 24 | 0.62× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $124.0M | $-847.0M |
| 自由现金流经营现金流 - 资本支出 | $99.0M | $-880.0M |
| 自由现金流率自由现金流/营收 | 15.2% | -86.6% |
| 资本支出强度资本支出/营收 | 3.8% | 3.2% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $250.0M | $-1.9B |
8季度趋势，按日历期对齐
经营现金流ALITMRNA
| Q4 25 | $124.0M | — | ||
| Q3 25 | $77.0M | $-847.0M | ||
| Q2 25 | $86.0M | — | ||
| Q1 25 | $73.0M | — | ||
| Q4 24 | $118.0M | $825.0M | ||
| Q3 24 | $-24.0M | $-1.6B | ||
| Q2 24 | $58.0M | — | ||
| Q1 24 | $100.0M | — |
自由现金流ALITMRNA
| Q4 25 | $99.0M | — | ||
| Q3 25 | $49.0M | $-880.0M | ||
| Q2 25 | $58.0M | — | ||
| Q1 25 | $44.0M | — | ||
| Q4 24 | $92.0M | $303.0M | ||
| Q3 24 | $-52.0M | $-1.7B | ||
| Q2 24 | $22.0M | — | ||
| Q1 24 | $69.0M | — |
自由现金流率ALITMRNA
| Q4 25 | 15.2% | — | ||
| Q3 25 | 9.2% | -86.6% | ||
| Q2 25 | 11.0% | — | ||
| Q1 25 | 8.0% | — | ||
| Q4 24 | 13.5% | 31.4% | ||
| Q3 24 | -9.4% | -92.2% | ||
| Q2 24 | 4.1% | — | ||
| Q1 24 | 12.3% | — |
资本支出强度ALITMRNA
| Q4 25 | 3.8% | — | ||
| Q3 25 | 5.3% | 3.2% | ||
| Q2 25 | 5.3% | — | ||
| Q1 25 | 5.3% | — | ||
| Q4 24 | 3.8% | 54.0% | ||
| Q3 24 | 5.0% | 8.1% | ||
| Q2 24 | 6.7% | — | ||
| Q1 24 | 5.5% | — |
现金转化率ALITMRNA
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 14.75× | — | ||
| Q3 24 | — | -120.46× | ||
| Q2 24 | 2.52× | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ALIT
| Recurring | $607.0M | 93% |
| Projects | $46.0M | 7% |
MRNA
| COVID19 | $971.0M | 96% |
| Other Revenue | $20.0M | 2% |
| Grant | $14.0M | 1% |
| Collaboration Arrangement Including Arrangements With Affiliate | $7.0M | 1% |
| License And Royalty | $2.0M | 0% |
